NEWS: Research Team Designing Holographic Imaging System for Ovarian Cancer
UA researchers
Jennifer Barton and Ray Kostuk have received a five-year, $2.4 million grant
from the National Institutes of Health to build the instrument that they hope
will one day be used to monitor women at high risk for ovarian cancer.
By Rebecca
Ruiz-McGill, University Communications
August 10, 2009
Two University
of Arizona researchers have formed a research team to design, build and
evaluate two versions of an ovarian cancer medical imaging and screening
instrument that will use holographic components in a new type of optical
microscope.
Raymond Kostuk
and Jennifer Barton have secured a five-year, $2.4 million grant from the
National Institutes of Health to build the instrument that they hope will one
day be used to monitor women at high risk for ovarian cancer. Kostuk is
the Kenneth Von Behren Professor of Electrical and Computer Engineering and
professor of optical sciences.
Barton heads the
UA department of biomedical engineering and is assistant director of the BIO5
Institute. She also is a member of the Arizona Cancer Center.
The system is
unique in that it will for the first time project multiple spatial images from
different depths within a tissue sample and simultaneously provide spectral
information from optical markers in order to better identify cancerous cells.
This combined
spectral spatial imaging technique shows potential to be much more effective in
identifying cancerous tissue sites than by separately using spatial or spectral
information.
The grant was
issued following the successful two-year development of a prototype system the
team built. It tests the validity of using holographic technology for
subsurface imaging without having to perform surgery and take tissue samples.
According to the
National Institutes of Health, there is, to date, no single effective screening
test for ovarian cancer, so ovarian cancer is rarely diagnosed in its early
stages. The result is that in more than 50 percent of women with ovarian cancer
are diagnosed in the late stages of the disease when the cancer has already
advanced.
- About
76 percent percent of women with ovarian cancer survive one year after
diagnosis.
- About
45 percent live longer than 5 years after diagnosis.
Barton said
ovarian cancer provides a compelling case to test holographic imaging and its
efficacy in detecting cancers. At the present time the preferred treatment is
surgery, which is also often needed to diagnose ovarian cancer. The procedure
includes taking tissue samples, which may threaten the woman's ability to have
children in the future.
"Ovarian
cancer has no symptoms until it is highly advanced making the five-year
prognosis extremely poor. Those at high risk – with a family history of
ovarian cancer or those who carry genetic mutations in the BRCA1 and BRCA2
genes, which normally help protect against both breast and ovarian
cancer – may be counseled to have their ovaries removed through
laparoscopic surgery," Barton said. "Now imagine if you are an
18-year-old woman who has this history – ovaries are an important part of
your overall health. They produce hormones you need over and above the notion
that you would need your ovaries should you want to have children in the
future."
Thus, new
technology capable of reliably diagnosing ovarian cancer in earlier stages
could reduce the morbidity, high mortality and economic impact of this disease.
The system will
work like a high-powered microscope that can be used to study tissue samples
already removed. In addition, an endoscopic version is in the design stage to
safely scan the ovaries for cancer during laparoscopic screenings in high-risk
women, or as an adjunct to other laparoscopic procedures in all women.
The team will
work with Dr. Kenneth D. Hatch, president of the Society of Pelvic Surgeons,
and a professor of obstetrics and gynecology and director of female pelvic
medicine and reconstructive surgery at the UA College of Medicine.
Through Hatch
and a partnership with his patients who consent, Barton and Kostuk will be able
to identify abnormal spatial and spectral markers of cancerous ovarian tissue.
The new imaging
system will be tested on high-risk patients who are willing to participate and
provide some future benefit to other patients who find themselves in a similar
situation, Barton said.
Kostuk and
Barton's aim is to design the imaging system so that it is easy to use,
requiring very little training, and also be cost effective.
"The system
will image like an MRI or a CT scan but with much higher resolution than an
ultrasounic image and will be a lot less expensive than an MRI. As an
additional benefit no radiation will be used or exposed to sensitive ovary
areas during the cancer screenings," Kostuk said.
During the past
25 years Kostuk has researched different aspects of holography and holographic
materials for use as optical elements.
The holographic
imaging system being designed combines an optical technique that creates images
capable of detecting subtle tissue microstructure changes. Together with
fluorescence spectroscopy methods, the system has demonstrated capability for
early cancer detection.
Another member
of the team, UA research professor Marek Romanowski, with the UA department of
biomedical engineering and the BIO5 Institute, is working on the development of
targeted fluorescent dyes that will be used on tissue samples to identify or
confirm suspected cancerous areas shown in the spatial image.
The
multidisciplinary approach to the design of the hologram-based imaging system
is a testament to the complexity of treating cancers.
"One of the
advantages of being part of the UA is the ability to interact collaboratively
with people in other disciplines," Kotuk said. "Jennifer is a
wonderful colleague who can identify important medical applications for new
techniques and is able to bridge the gap between traditional engineering and
medicine. Her skill and knowledge is critical to the success of the
program," he said.
"To solve
the really interesting problems of today, no one person has all the expertise
needed," Barton added.
<< Home